Avtor/Urednik		Meden-Vrtovec, H
Naslov		GnRH analog administration in patients with polycystic ovarian disease
Tip		članek
Vir		Int J Gynaecol Obstet
Vol. in št.		Letnik 50
Leto izdaje		1995
Obseg		str. 179-83
Jezik		eng
Abstrakt		To evaluate the hormonal response to the short protocol of gonadotropin-releasing hormone (GnRH) analog (GnRHa) in patients with polycystic ovarian disease (PCOD). Methods: We enrolled 35 patients (20 infertile) with ultrasonographic and hormonal PCOD characteristics. GnRHa Suprefact was applied subcutaneously at a daily dose of 0.9 ml for 9 consecutive days starting on the 10th-15th day after induced or spontaneous bleeding. Blood samples for follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), estradiol (E2), estrone (E1) and dehydroepiandosterone sulfate (DHEA-S) was performed before the treatment and on days 3 and 4 of GnRHa administration. Student's t-test was used for the analysis of differences between various mean values. All statistical analyses were performed by the computerized statistical package CSS-Statistica. Results: Pretreatment hormonal levels (FSH 5.6+-1.86 IU per l, LH 14.16+-1.72 IU per l, E2 0.29+-0.20 nmol per l, E1 0.35+-0.17 nmol per l, T 3.52+-1.40 nmol per l, DHEA-S 7.15+-2.89 micromol per l) barely differed on day 3 of GnRHa administration, except for the rise in LH (17.14+-10.97 IU per l), which was still not significant. On day 9 of GnRHa application, significant suppression of FSH (3.16+-1.55 IU per l) and LH (8.05+-5.00 IU per l) was registered compared with pretreatmet levels, without changes in the FSH:LH ratio, and in other parameters studied. Although there were no changes in ultrasound characteristics on day 9 of GnRHa administration compared with basal findings, bleeding occured 14-18 days after the last GnRHa
Deskriptorji		POLYCYSTIC OVARY SYNDROME GONADORELIN FSH LH TESTOSTERONE ESTRADIOL ESTRONE PRASTERONE ADULT MENSTRUATION DISORDERS